Why the study?
Inflammation is a common link between obesity and cardiovascular diseases, driven by adipose tissue dysfunction and aberrant adipokine release.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Adipokines may inform inflammation assessment in obese CVD patients; leaves open targeted therapies pending prospective validation.
It is well established that adipose tissue, apart from its energy storage function, acts as an endocrine organ that produces and secretes a number of bioactive substances, including hormones commonly known as adipokines. Obesity is a major risk factor for the development of cardiovascular diseases, mainly due to a low grade of inflammation and the excessive fat accumulation produced in this state. The adipose tissue dysfunction in obesity leads to an aberrant release of adipokines, some of them with direct cardiovascular and inflammatory regulatory functions. Inflammation is a common link between obesity and cardiovascular diseases, so this review will summarise the role of the main adipokines implicated in the regulation of the inflammatory processes occurring under the scenario of cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Feijóo‐Bandín et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: